Welcome to the CAPRELSA REMS Program
CAPRELSA® (vandetanib) Tablets, a kinase inhibitor, is approved by the Food and Drug Administration (FDA) for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease. Use of CAPRELSA in patients with indolent, asymptomatic or slowly progressing disease should be carefully considered because of the treatment related risks of CAPRELSA.
CAPRELSA can prolong the QT interval and cases of Torsades de pointes and sudden death were reported in clinical trials. Because of this risk, CAPRELSA is only available through the CAPRELSA Risk Evaluation and Mitigation Strategy (REMS) Program. Read more.
The CAPRELSA REMS Program has the following specific goals:
- To educate prescribers about the risk, appropriate monitoring, and management of QT prolongation to help minimize the occurrence of Torsades de pointes and sudden death
- To inform patients about the serious risks associated with CAPRELSA
Under the CAPRELSA REMS Program, only certified prescribers can prescribe CAPRELSA.